PL3058374T3 - Sposób rozpoznawania hiperaldosteronizmu pierwotnego - Google Patents

Sposób rozpoznawania hiperaldosteronizmu pierwotnego

Info

Publication number
PL3058374T3
PL3058374T3 PL14789218T PL14789218T PL3058374T3 PL 3058374 T3 PL3058374 T3 PL 3058374T3 PL 14789218 T PL14789218 T PL 14789218T PL 14789218 T PL14789218 T PL 14789218T PL 3058374 T3 PL3058374 T3 PL 3058374T3
Authority
PL
Poland
Prior art keywords
diagnosis
primary hyperaldosteronism
hyperaldosteronism
primary
Prior art date
Application number
PL14789218T
Other languages
English (en)
Inventor
Marko POGLITSCH
Cornelia SCHWAGER
Dunja VAN OYEN
Martin Leitner
Original Assignee
Attoquant Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20130189386 external-priority patent/EP2863228A1/en
Application filed by Attoquant Diagnostics Gmbh filed Critical Attoquant Diagnostics Gmbh
Publication of PL3058374T3 publication Critical patent/PL3058374T3/pl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743Steroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483Physical analysis of biological material
    • G01N33/487Physical analysis of biological material of liquid biological material
    • G01N33/49Blood
    • G01N33/492Determining multiple analytes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2410/00Assays, e.g. immunoassays or enzyme assays, involving peptides of less than 20 animo acids
    • G01N2410/02Angiotensins; Related peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Ecology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL14789218T 2013-10-18 2014-10-17 Sposób rozpoznawania hiperaldosteronizmu pierwotnego PL3058374T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP20130189386 EP2863228A1 (en) 2013-10-18 2013-10-18 Method for diagnosis of primary hyperaldosteronism
EP14152763 2014-01-28
PCT/EP2014/072339 WO2015055825A1 (en) 2013-10-18 2014-10-17 Method for diagnosis of primary hyperaldosteronism
EP14789218.6A EP3058374B1 (en) 2013-10-18 2014-10-17 Method for diagnosis of primary hyperaldosteronism

Publications (1)

Publication Number Publication Date
PL3058374T3 true PL3058374T3 (pl) 2020-02-28

Family

ID=51794861

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14789218T PL3058374T3 (pl) 2013-10-18 2014-10-17 Sposób rozpoznawania hiperaldosteronizmu pierwotnego

Country Status (13)

Country Link
US (2) US9829496B2 (pl)
EP (1) EP3058374B1 (pl)
JP (1) JP6397907B2 (pl)
CN (1) CN105683760A (pl)
AU (1) AU2014336122B2 (pl)
BR (1) BR112016007960B8 (pl)
CA (1) CA2926382C (pl)
DK (1) DK3058374T3 (pl)
EA (1) EA035289B1 (pl)
ES (1) ES2745099T3 (pl)
HU (1) HUE045337T2 (pl)
PL (1) PL3058374T3 (pl)
WO (1) WO2015055825A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10559377B2 (en) 2013-01-09 2020-02-11 Biomed Concepts Inc. Graphical user interface for identifying diagnostic and therapeutic options for medical conditions using electronic health records
EA035289B1 (ru) * 2013-10-18 2020-05-25 Аттоквант Диагностикс Гмбх Способ диагностики первичного гиперальдостеронизма
EP3405894A1 (en) * 2016-01-19 2018-11-28 Biomed Concepts Inc. Method and system for identifying diagnostic and therapeutic options for medical conditions using electronic health records
CA3041724C (en) * 2016-11-17 2022-05-31 Laboratory Corporation Of America Holdings Methods and systems for measuring plasma renin activity
CN106770824A (zh) * 2016-12-21 2017-05-31 河南出入境检验检疫局检验检疫技术中心 利用高分辨质谱仪检测血浆中痕量醛固酮的方法
JP7067758B2 (ja) * 2017-06-30 2022-05-16 国立大学法人 新潟大学 試料中のアンジオテンシンペプチドの量を測定するための方法及びアンジオテンシンペプチドの定量キット
CN112037931B (zh) * 2020-07-15 2023-10-20 新疆维吾尔自治区人民医院 在疑似原发性醛固酮增多症中应用的醛固酮增多预测体系
AU2021325340A1 (en) * 2020-08-10 2023-04-13 Proteomedge Ab Solid mixture comprising standard protein
CN112014509A (zh) * 2020-09-03 2020-12-01 复旦大学附属中山医院 同步测定样品中血管紧张素i和醛固酮的方法
CN113533552B (zh) * 2021-06-02 2023-08-29 杭州凯莱谱精准医疗检测技术有限公司 液相色谱串联质谱检测肾素活性过程中对影响arr药物同步检测的方法
CN118922718A (zh) * 2021-10-19 2024-11-08 菲诺米耐斯公司 使用磁珠进行简单的可自动化的蛋白质消化的系统和方法
CN117031028A (zh) * 2023-07-25 2023-11-10 深圳市科曼医疗设备有限公司 醛固酮检测用解离试剂以及醛固酮化学发光检测试剂盒
CN117554603B (zh) * 2023-11-28 2024-05-10 中国医学科学院阜外医院 一种用于原发性醛固酮增多症初筛的标志物组合及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3919407A (en) * 1973-11-28 1975-11-11 De Castro Aurora L Fernandez Method for quantitative determination of renin activity in blood
JPH022935A (ja) * 1988-06-20 1990-01-08 Tosoh Corp アンジオテンシンの測定法
US5314804A (en) * 1992-03-24 1994-05-24 Serim Research Corporation Test for Helicobacter pylori
AU2002304965A1 (en) * 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
WO2007109733A2 (en) * 2006-03-21 2007-09-27 The Johns Hopkins University Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
KR20090020559A (ko) 2006-05-29 2009-02-26 니콕스 에스. 에이. 엔도셀린 수용체 길항제로서의 질화 헤테로시클릭 화합물
EP2129382A4 (en) 2007-02-21 2011-01-19 Univ Michigan COMPOSITIONS AND METHODS FOR HEART MUSCLE PREVENTION
EP2225559B8 (en) * 2007-12-28 2016-12-21 F. Hoffmann-La Roche AG Assessment of physiological conditions
US9883909B2 (en) * 2012-03-08 2018-02-06 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation methods and systems for treatment of hyperaldosteronism
CN102586223A (zh) 2012-03-08 2012-07-18 南京大学 一种基于mypt1基因敲除建立新型高血压小鼠模型的方法及其用途
EA035289B1 (ru) * 2013-10-18 2020-05-25 Аттоквант Диагностикс Гмбх Способ диагностики первичного гиперальдостеронизма

Also Published As

Publication number Publication date
HUE045337T2 (hu) 2019-12-30
DK3058374T3 (da) 2019-08-26
WO2015055825A1 (en) 2015-04-23
NZ717888A (en) 2022-03-25
EP3058374B1 (en) 2019-06-26
EA201690796A1 (ru) 2016-08-31
BR112016007960A8 (pt) 2020-03-17
CA2926382C (en) 2020-06-02
BR112016007960B8 (pt) 2023-11-14
US20160266151A1 (en) 2016-09-15
ES2745099T3 (es) 2020-02-27
BR112016007960B1 (pt) 2023-03-07
JP2017500538A (ja) 2017-01-05
AU2014336122B2 (en) 2020-06-25
AU2014336122A1 (en) 2016-04-07
CN105683760A (zh) 2016-06-15
CA2926382A1 (en) 2015-04-23
JP6397907B2 (ja) 2018-09-26
EA035289B1 (ru) 2020-05-25
US20180164330A1 (en) 2018-06-14
US9829496B2 (en) 2017-11-28
EP3058374A1 (en) 2016-08-24
US10295552B2 (en) 2019-05-21

Similar Documents

Publication Publication Date Title
PL3058374T3 (pl) Sposób rozpoznawania hiperaldosteronizmu pierwotnego
SG10201801428RA (en) Method for increasing expression of rna-encoded proteins
GB201401248D0 (en) Method of manufacture
LT3011051T (lt) Genetinių variacijų neinvazinis vertinimo būdas
IL279291A (en) Morphic forms of hexadecyloxypropyl-phosphonate esters
GB201412190D0 (en) Method of optimization for an application
IL235115A0 (en) A method for the preparation of imidodisulfuryl compounds
PL3071969T3 (pl) Sposób analizy
EP2981374A4 (en) CASTING METHOD
GB201319875D0 (en) Method of measuring isotape ratio
GB201305231D0 (en) Method of Manufacture
IL241096B (en) Treatment methods
GB2518928B (en) Method of depilation
ZA201601775B (en) Method for the synthesis of irinotecan
GB201307256D0 (en) Diagnostic method
GB201323123D0 (en) Method for the preparation of biopolymers
GB201509658D0 (en) Method of diagnosis
GB2524357B (en) Method of charge state selection
IL241475A0 (en) method for synthesis
GB201221046D0 (en) Method of diagnosis
GB201300370D0 (en) Method of calibrating asynchronies
GB201311291D0 (en) Method of manufacture
GB201301262D0 (en) Method of manufacture
SG10201701021XA (en) Method of synthesis
GB201400510D0 (en) Method of providing broadband connection